Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 12/20 | 0.53 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | TYK2 | P29597 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24010234 | 0.90 | BRAF (0.55) | BRAFMEN1KMT2A | |
| SCHEMBL24006426 | 0.88 | ACVRL1 (0.53) | BRAFJAK2TYK2KDM4CMAPT | |
| SCHEMBL26322741 | 0.86 | POLB (0.53) | BRAFJAK2TYK2HDAC3HDAC1 | |
| SCHEMBL24010619 | 0.83 | GRM5 (0.55) | BRAFHDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL1520310 | 0.83 | NPC1 (0.65) | NPC1RAB9AALDH1A1KDM4EMEN1 | |
| SCHEMBL25821615 | 0.83 | ACVRL1 (0.54) | BRAFMAPT | |
| SCHEMBL30290852 | 0.81 | BRAF (0.61) | BRAFMEN1KMT2A | |
| SCHEMBL24010908 | 0.81 | BRAF (0.61) | BRAFMEN1KMT2A | |
| SCHEMBL24004057 | 0.79 | ABL1 (0.57) | BRAFHDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL26322770 | 0.79 | MAPK8 (0.48) | JAK2TYK2HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
| WO-2021226458-A1 | AKT3 MODULATORS | GEORGIAMUNE LLC (US) | 2021-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | AKT3, AKT2, PIK3CA | BRAF 154/4885JAK2 522/4885TYK2 2961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.